Study finds no incremental benefit of an percutaneous coronary intervention or coronary artery bypass grafting in patients with stable coronary disease and advanced chronic kidney disease.
The reduction in left ventricular mass observed in patients with stable coronary artery disease and type 2 diabetes treated with empagliflozin may not result of an effect of this drug on diastolic function.
Genetic testing is not better at predicting coronary heart disease risk compared with conventional risk factors.
The treatment of proximal left anterior descending coronary artery lesions using new-generation drug-eluting stents was not found to be associated with higher rates of adverse clinical events at 2 years.
The majority of patients with acute coronary syndrome treated with statins were found to have low-density lipoproteins-cholesterol levels above those recommended by current guidelines.
For patients with stable coronary disease and moderate-to-severe ischemia, an initial invasive strategy does not improve outcomes, but it may improve angina-related health status.
18F-sodium fluoride coronary positron emission tomography may help predict the development of myocardial infarction in patients with advanced coronary artery disease.
Presence of diabetes before liver transplantation may be an independent predictor of sudden cardiac death after the procedure.
Renal insufficiency may be linked to reduced circulating progenitor cell counts, a factor indicative of impaired regenerative capacity in older adults with coronary artery disease.
The incidence of major adverse cardiac events was found to be associated with levels of lipoprotein(a) in patients with diabetes who are prescribed statin medications for coronary artery disease, following percutaneous coronary intervention.